Method of hepatic failure treatment

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to efferent therapy, and can be applied in treatment of patients with hepatic failure after performed cardio-surgical operation. For this purpose realised is veno-venous hemofiltration with application of standard bicarbonate solution. If clinical and laboratory signs of hepatic failure increase following sessions of hemofiltration are carried out during 5-8 hours with application of dialytic solution based on standard bicarbonate solution with 2% content of albumen. After session of hemofiltration with such solution, laboratory control of basic functional hepatic indices is performed. In case of necessity additional sessions with application of dialytic solution which contains 2% albumen are carried out.

EFFECT: method makes it possible to increase efficiency of small-flow veno-venous hemofiltration due to increase of clearance of endotoxins, associated with blood plasma proteins.

2 cl, 2 ex

 

The invention relates to medicine, in particular to anesthesiology and critical care medicine, and can be used in the treatment of liver failure, such as patients after cardiac surgical procedures.

Despite the success of modern intensive care, the mortality of patients with acute liver failure or acute decompensation of chronic liver failure, remains unacceptably high and is not reduced below 60%, even in specialized Hepatology centers. According to the world health organization among the causes of death liver failure occupies the sixth place. The reason for the high mortality are complications, joining with progression of the underlying disease leading to development of multiple organ failure in the terminal stage of chronic diffuse liver disease. Decompensation of chronic liver disease is often associated with multiple organ dysfunction, including hemodynamic instability, renal and cerebral dysfunction, which leads to a high risk of death. Critical conditions associated with severe hypoxia internal organs, their complicated by damage to varying degrees. The loss of function of detoxification systems (kidneys and is echani) entails the progression of endotoxemia, development gistologicheskoe hypoxia and the aggravation of disorders of gas exchange in all organs and systems, including in the detoxification organs. Thus, a vicious circle that defines the extremely high mortality in acute renal and hepatic and renal insufficiency. Change the results of the treatment can only preventing and eliminating hypoxic effects on organs and systems, including detoxification organs.

The creation and use of artificial support systems of the liver is the main idea of modern intensive care patients with liver failure, which helped reduce mortality from 85 to 60%.

The known method of sorption detoxification, based on the perfusion of blood through the coal or synthetic sorbents (Collection of articles, 2009. - VIP. 1. - S-311). When sorption detoxification of blood or plasma sorbent effectively removes metabolites middle and large molecular weight, hydrophobic, lipid-soluble and proteinsathome toxic complexes. The disadvantages of the method are the lack of selectivity excretion of metabolites inside the sorbent through its transport pores penetrate and are fixed on the surface of a variety of substances: enzymes, vitamins, hormones, therefore, detoxification is usually accompanied by the disruption of homeostasis. In about the Jesse sorption injured and the formed elements of blood, mainly leukocytes and platelets, to a lesser extent erythrocytes and lymphocytes, the number of which decreases accordingly output from the column with sorbent by 40-70% and 18-25%. In patients after operations in conditions of artificial blood circulation and phenomena cytopenia, including thrombocytopenia, anemia and forced medication gipokoagulyatsii, the use of sorption is extremely dangerous and not always effective.

Known methods of plasmapheresis, in which gravity or filtration removal (apheresis) from the bloodstream of a certain number of plasma after pre-separation of blood into a liquid portion and shaped elements, with the return to the vascular system of the latter (MONICA. Discrete exchange plasmapheresis. http://monikiweb.ru/SPNec/diskretn.htm. - P.1-6). For plasmapheresis is correction of volemic violations related plasmopara, filling of the volume of circulating blood. The disadvantage of this method is the high frequency of adverse reactions (5% of cases)due gipokaltsiemiey due to the introduction of blood citrate solution, cooling the blood and fluids in the in vitro system, the change in fluid balance (Hypo - and hypervolemia) and electrolytes. Overdose of anticoagulants may cause hemorrhage and insufficient dose of thrombosis. One of p is etiopathogeny to plasmapheresis believe decompensated state of the cardiovascular system, acute cerebrovascular accident, hypertensive crisis, neuro-psychiatric disorders - just the basic components postoperative multiple organ failure in cardiac surgery.

Closest to the claimed method is a method albumen dialysis or molecular adsorbent recirculating system - a method of extracorporeal detoxification, combining the efficiency of the sorbent, which is albumin, and the biocompatibility of modern dialysis membranes (Tretyakov BV System recoil molecular adsorption "MARS" - albumin mediate the method of hemodiafiltration / Bvitlv, Snitow // http://www/mks.ru/library/conf/biomedpribor/2008/sec.08-13.html, c.1-6)

Unlike hemodialysis and hemosorption in this system incorporates the principle of mediated detoxification through a special high-permeability membrane. The blood perfusion is carried out inside the capillaries of dialysator, while outside the role of dialysate performs donor albumin. The concentration gradient is the diffusion of toxic substances through a semipermeable membrane from the blood into the outer albumen path, taking toxins. Due to the limited permeability (50 kDa) pass through the membrane only substances with low and medium molecular weight, which allows to avoid the loss and the gene functional molecules. In the subsequent by recirculation through a conventional dialysator, sorbent and anion-exchange resin regeneration is binding capacity saturated with toxins donor albumin. Key technologies MARS is moving through a modified highly permeable dialysis membrane toxins that have affinity to albumin from the blood to an acceptor. Acceptor donor is human albumin circulating in a closed loop. Water-soluble low molecular weight substances are removed by concentration gradient, as in dialysis.

Unlike hemodialysis, which has only two paths - the blood of the patient and the dialysis fluid during the procedure according to the technology of MARS, there are three circuits: the blood of the patient, dialysis fluid and albumen circuit. Through intermediate albumen circuit and is mediated, i.e. out of direct contact with blood, excretion of both water-soluble and protein-bound toxins. The main disadvantage of this method is the high cost of equipment and consumables and, as a consequence, marginal profitability of such procedures in specialized centers not involved in liver transplantation.

The technical result of the invention is to improve the efficiency of small-flow anesthesia veno-venous hemodiafiltration the ri liver failure by eliminating the need for additional equipment and consumables.

A method of treatment of patients with liver failure after cardiac interventions, including veno-venous hemodiafiltration using standard bicarbonate dialysis solution.

The difference is that with the increasing clinical and laboratory signs of hepatic failure subsequent hemofiltration hold for 5-8 hours using a dialysis solution on the basis of standard bicarbonate solution with 2%containing albumin.

The difference is that after each session of dialysis solution with 2%albumin conduct laboratory control of the main functional liver enzymes and if necessary, conduct re-use dialysis solution with 2%albumin.

Holding hemodiafiltration dialysis solution containing 2%albumin, significantly increases the clearance of endotoxin associated with plasma proteins and allows you to abortirovat ' or clinically to reduce the symptoms of hepatic insufficiency in patients with multiple organ failure after cardiac interventions.

The essence of the proposed method lies in the fact that patients with multi-organ failure after cardiac interventions malapit is CNA veno-venous HDF is the method of choice basic intensive therapy. Specific interventions and pathology prevents the effective use of sorption or afferent methods of detoxification. With the increasing clinical and laboratory signs of hepatic failure within hemodiafiltration held 5-8-hour session on dialysis solution with 2%albumin. To do this in standard bicarbonate dialysis solution is added 20%albumin to create a 2%-aqueous solution. The HDF is performed with the same flow of 150-200 ml/min at rated heparinisation (IU/kg) in 50% postdilution when the flow of substituate and dialysis solution is not less than 35-45 ml/kg/h, when necessary for each individual patient's rate of ultrafiltration. At the end of the dialysis session with a 2%solution of albumin within 12-24 h under laboratory control of the main functional liver enzymes and continuing hemofiltration may re-use of albumen dialysis solution.

Example 1.

Patient T., 66 years old, no history of the disease 902, was admitted to the intensive care unit 13.02.2009 with a diagnosis of Coronary heart disease, angina 4th functional class, postinfarction koronarokardioskleroze, mitral valve insufficiency, 2nd functional class, NCB, constant form of atrial fibrillation. Operation in conditions of art the venous circulation: coronary artery bypass grafting, plastic mitral valve, radiofrequency ablation, perioperative myocardial infarction, cardiogenic shock, intra-aortic balloon counterpulsation. The postoperative period was complicated by bleeding requiring resternotomy with additional hemostasis and massive, up to 8 doses of erythrocyte mass, blood transfusion. To 24 h postoperative period the patient detailed picture of multiple organ failure with the prevalence of heart failure syndrome (small release), syndrome of acute lung injury (rdsw), ARF (oligoanuria less than 0.5 ml/kg/h during stimulation of 10 mg/kg lasixa), concerning which started HDF apparatus Prismaflex" (Gambro, Sweden) in 50% postdilution solution "Prismasol-2" when the speed of flow of 180 ml/min ultrafiltration 100 ml/h, the flow dialysate and substitute 40 ml/kg/h With a gradual stabilization of core functions to third day of the postoperative period the patient has prevailed clinic developing liver failure - was growing interesest of sclera and skin, is bilirubin increased to 200 g/l, mainly due to the direct fraction; at high transaminase - ACT 176 ME, ACT 142 ME;-glutamyltranspeptidase (GGT) to 90.7 ME, alkaline phosphatase 5.1 µkat/l and the reduction of coagulation parameters. Conducted an eight-hour session with inclusion in Ontur hemodiafiltration 2%albumen dialysis with a dialysis solution flow 1 l/H. At the end of albumen dialysis bilirubin decreased by 30% to 147 g/l with persistent high values of transaminases - ACT 132, 118 ALT, GGT 74,5 ME; alkaline phosphatase 3.9 µkat/l, so after 20 h was a repeat session with 2%albumin for 6 hours At the end of the session performance bilirubin was slightly higher than normal - 50.6 g/l (indirect fraction 35.5 g/l), and the values transaminase was on the upper limit of the norm - ACT 45,8, ALT 39,1 ME. After 19 days the patient was transferred to the Department of surgery in the absence of signs of hepatic failure requiring conservative treatment.

Example 2.

Patient A., 53 years of age, no history of the disease 1136, was admitted to the intensive care unit 13.02.2009 with a diagnosis of Dysfunction of Bioprocess in the mitral position, the insufficiency of tricuspid valve, 2-St functional class, NCB-3, pulmonary edema, bilateral hydrothorax, urolithiasis, CRF 0-1. Operation in an emergency: reputazione mitral valve, annuloplasty tricuspid valve. In connection with problems of re-access duration of cardiopulmonary bypass exceeded 210 minutes In the postoperative period for 12 h against the background of significant systemic inflammatory response anuria, rdsw, dissidia, concerning which started HDF apparatus Prismaflex in 50% postdilution fixed flow sub is titoite "Prismasol-2" to 40 ml/kg, dialysate 1 l/h at the start of ultrafiltration 50 ml/h, the flow velocity of 185 ml/min (min 150, max 200) at a metered bolus of heparinization at the level of ACT 180±20 C. during the first postoperative day the patient was growing clinical and biochemical indices of liver failure is the appearance of isterichnost sclera and skin; total bilirubin from 74.4±12.9 to reach 232.5±28,2 g/l (with a predominance of indirect fraction); ACT 86,5±20 to 181,5±35,5 ME; ALT with 51,3+15.5 to 155±45 ME; alkaline phosphatase (apase) from 2.7+1.9 µkat/l to 3,65+1,1;-glutamyltranspeptidase (GGT) from 57.2±16,4 to 61.8+15,8 ME while reducing total protein from 56.5±9,9 to 42±10,5 g/l (albumin less than 50%), which was the indication for the start of dialysis with 2%solution of albumin. The duration of the treatment of 10 hours at a flow of dialysate 1 l/h after the procedure (continued hemodiafiltration) obtained a decrease in total bilirubin to baseline - 82±12 g/l with almost normalization of transaminases - ACT 46,5+10,5 ME; ALT 37±12,5 ME; alkaline phosphatase 2,55±1,15; GGT 53,3±10,9 (total protein 61±9.3 g/l, albumin 62±8%). Upon further observation for 2-3 days after hemodiafiltration increased rates of bilirubin (96,7±16.3 g/l) and transaminase (ACT OF 58.9±9,1 ME, ALT 48,4+11,5), but the increase did not wear resistant, and in the standard conservative therapy the patient on the 20th day transferred to the Department of surgery.

1. The method of treatment pictocin the th failure after cardiac surgery interventions including sessions veno-venous hemofiltration using standard bicarbonate solution, characterized in that with the increasing clinical and laboratory signs of hepatic failure subsequent hemofiltration hold for 5-8 h using a dialysis solution on the basis of standard bicarbonate solution with 2%albumin.

2. The method according to claim 1, characterized in that after the session hemofiltration dialysis solution containing 2%albumin, perform laboratory monitoring of the main functional liver enzymes and, if necessary, conduct refresher sessions using dialysis solution containing 2%albumin.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to abdominal surgery, hepatology and methods of detoxication, and can be applied for treatment of liver abscess of different etiology. For this purpose after sanitisation of purulent nidus cavity of liver abscess is processed with 0.25% solution of derinate, then blood sampling is carried out in quantity 150-200 ml of blood, after centrifugation of which erythrocytes are returned to patient, and leucocytes are extra-corporeally processed with 0.5% solution of glutoxim in dose 1 ml and diluted in 50-100 ml of 0.9% solution of NaCl with following intravenous drop introduction, and from the following day into cavity introduced is 0.25% solution of derinate in dose 1.5 ml one time per day during 5 days.

EFFECT: method makes it possible to reduce treatment duration and reduce number of complications due to improvement of indices of cellular link activity, connected with increase of quantitative indices of T-helpers and T-suppressors at the background of increase of phagocytic activity of neutrophils, as well as reduction of erythrodieresis processes due to normalisation of APFC content and humoral link of immunity.

2 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula I, which are HSP90 (heat-shock proteins) inhibitors and can be used to prepare a medicinal agent for treating tumorous diseases affected by HSP90 inhibition. In formula I R1 denotes Hal, H, OA or A, R2, R3 each independently denotes -O-(X)s-Q, -NHCO-(X)s-Q, -CONH-(X)s-Q, -NH(CO)NH-(X)s-Q, -NH(CO)O-(X)s-Q, -NHSOr(X)s-Q, NHCOA, Hal, Het or H, where, if R2=H, then R3≠H, or if R3=H, then R2≠H, R4 denotes H, R5 denotes H, Hal, A, OA, (CH2)nCOOH, (CH2)nCOOA, O(CH2)oCONH2, NHCOOA, NHCO(CH2)nNH2, NHCONHA or O(CH2)oHet1, A denotes a straight or branched alkyl containing 1-10 carbon atoms, in which 1-5 hydrogen atoms may be substituted with F, Cl and/or Br, X denotes a straight or branched C1-C10 alkylene which is unsubstituted or substituted once, twice or thrice by A, O A, OH, Hal, CN, COOH, COOA, CONH2, NH2, NHCOA, NHCOOA, Q denotes H, Ar or Het, Ar denotes phenyl which is unsubstituted or substituted once, twice or thrice with A, OA, OH, NO2, Hal, CN, (CH2)nCOOH, (CH2)nCOOA and/or tetrazole, Het denotes a cyclic saturated or aromatic 5-6-member heterocycle containing 1-2 N and/or O atoms, optionally condensed with a benzene ring which may be substituted once, twice or thrice with A, OA, OH and/or =O (carbonyl oxygen), Het1 denotes a monocyclic saturated, unsaturated or aromatic heterocycle containing 1-2 N and/or O atoms, which may be mono- or disubstituted with A, OA, OH, Hal and/or =O (carbonyl oxygen), Hal denotes F, Cl, Br or I, n equals , 1, 2, 3 or 4, o equals 1, 2 or 3, s equals 0, 1 or 2.

EFFECT: high efficiency of using said derivatives.

4 cl, 4 dwg, 1 tbl, 29 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to drugs, and concerns a therapeutic agent for treating hepatitis containing 2-amino-2-[4-3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediole or its pharmaceutically acceptable salt, or hydrate as an active ingredient. Also, disclosed is a method of treating hepatitis by introducing to a patient an effective amount of the therapeutic agent 2-amino-2-[4-3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediole or its pharmaceutically acceptable salt, or hydrate as an active ingredient.

EFFECT: therapeutic agent shows a stronger effect in treating hepatitis as compared to the other analogues.

4 cl, 3 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and is intended for treatment of gastroesophageal reflux disease (GERD) in patients with chronic opisthorchosis. PH-monitoring of upper parts of GIT and dehelmintisation are carried out. Type of reflux is determined. Preparations of ursodeoxycholic acid (UDCA) are administered. In case of mixed type of GER with prevalence of acid component dose is 250 mg/day for 2 weeks. In case of mixed type of GER with prevalence of alkali component dose is 500 mg/day before going to bed for 4 weeks. In isolated alkali version dose is 10 mg/kg in two intakes: morning and evening. In case of tgenpH>7 from 16.54 to 27.6%; NpH>7 from 27 to 31, and GER tgenpH>7 from 27.6 to 48.8%; NpH>7 from 31 to 35 - for 4 weeks. In case of tgenpH>7 from 16.54 to 27.6%; NpH>7 from 27 to 31, and GER tgenpH>7 from 27.6 to 48.8%; NpH>7 from 31 to 35 and in case of GER tgenpH>7 from 48.8 to 74.4%, NpH>7 from 36 to 42 - for 8 weeks. In case of tgenpH>7 from 48.8 to 74.4%; NpH>7 from 36 to 42, and GER tgenpH>7 from 16.54 to 74.4%; NpH>7 from 27 to 42 -for 12 weeks.

EFFECT: method makes it possible to reduce motor-tonic disturbances of biliary tract, reduce number of recurrences, enhance treatment efficiency.

4 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of pharmacy, in particular to phytotherapy, and can be applied for treatment of drug hepatitis. Medication represents herbal mixture, including 29 herbs: herbal part of woodland strawberry, herbal part of common dandelion, inflorescences of pineapple weed, leaves of stinging nettle, inflorescences of tansy, inflorescences of pot marigold, fruits of common juniper, peppermint leaves, herbal part of St John's wort. Medication additionally contains: lime tree flowers, herbal part of heartsease, herbal part of Centaurium, flax seeds, dill seeds, burdock root, herbal part of common chicory, herbal part of common knotgrass, collective fruits of common hop, herbal part of cornflower, leaves of cowberries, leaves of Arctostaphylus, corn stigma, herbal part of immortelle, root and rhizome of Acorus, herbal part of Menyanthes, garden angelica root, herbal part of yellow sweet clover, Inula root, herbal part of common horsetail.

EFFECT: mixture reduces terms of hepatitis treatment, as well as improves clinico-laboratory indices due to normalisation of liver function tests and functional state of liver.

4 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine. Mixture consists of medicinal plants: inflorescences of pot marigold, peppermint leaves, Baikal skullcap root, black leaves and root of badan, shoots of shrubby cinquefoil, with the following component ratio, wt fr.: inflorescences of pot marigold 3; peppermint leaves 1; Baikal skullcap root 2; rhizome and black leaves of badan - 1+1; shoots of shrubby cinquefoil 2. Clinical treatment with claimed mixture has resulted in positive effect in case of alcoholic hepatitis in 150 patients.

EFFECT: creation of mixture for treatment and prevention of alcoholic hepatitis.

10 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of medication, which possesses hepatoprotective, detoxicating and regenerating action. Medication contains in its composition essential phospholipids, vitamin B1, vitamin B2, vitamin B6, vitamin E, extract of milk thistle, extract of artichoke and auxiliary substances. Claimed medication extends arsenal of hepatoprotective medications, which possess wide pharmacologic spectrum of action.

EFFECT: medication corresponds to polyvalency of disease pathogenesis, affects patient's organism as a whole as corrective system.

2 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to therapy of internal non-transmitting diseases, particularly to drugs for pig hepatosis prevention. The agent for pig hepatosis prevention contains the ingredients in the following relation: antihepatotoxic serum 0.9-1.15 titre units; antisplenotoxic serum 0.9-1.15 titre units; leukocyte plasma 90-110 embryo units; phenol 0.004-0.005 mg; physiologic saline up to 1 ml.

EFFECT: invention allows higher effectiveness of pig hepatosis prevention.

4 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula (I) , where the dotted line is either absent or denotes a double bond; R1 denotes H or C1-6-alkyl, possibly substituted with a CN group, or denotes a phenyl or sulphonyl phenyl, substituted with one or more B groups, or denotes -(CH2)m-Ra, where Ra denotes: NRiRii, C3-6-cycloalkyl, 6-member heterocycloalkyl, which denotes a univalent saturated group which contains one nitrogen heteroatom, the rest are carbon atoms, aryl, which can be substituted with one or more B groups, or denotes -(CH2)n-(CO)-Rb or -(CH2)n-(SO2)-Rb, where Rb denotes: NRiRii, 5-6-member heterocycloalkyl, which denotes a univalent saturated group containing one or more heteroatoms selected from nitrogen, oxygen, the rest are carbon atoms, aryl or 5- or 6-member heteroaryl, which denotes an aromatic ring containing two heteroatoms as ring members, the said heteroatoms selected from N or O, the rest are carbon atoms; which can possibly be substituted with one or more B groups, R2 denotes one or more H, halo, C1-6-alkyl, C1-6-alkoxy, R3 denotes H or-(CO)-Rc, where Rc denotes: C1-6-alkyl, 5-member heterocycloalkyl, which denotes a univalent saturated group containing one nitrogen heteroatom, the rest are carbon atoms possibly substituted with C1-6-alkyl, or denotes C1-6-alkyl; R4 denotes H; R5 denotes H, C1-6-alkyl, -(CH2)m-NRiRii, -(CH2)n-(CO)-Rb, where Rb denotes NRiRii or a 6-member heterocycloalkyl which denotes a univalent saturated group which contains one nitrogen heteroatom, the rest are carbon atoms, when the dotted line is absent or is absent when the dotted line denotes a double bond; R6 is absent, when the dotted line denotes a double bond; R7 denotes Cl or NReRf, where Re and Rf denotes H or C1-6-alkyl, or Re and Rf together with the nitrogen atom to which they are bonded form a 6-member heterocycloalkyl which denotes a univalent saturated group containing one or two heteroatoms selected from nitrogen, oxygen, the rest are carbon atoms; which can be substituted with C1-6-alkyl, or R6 and R7 together form a C=O group, when the dotted line is absent; B denotes halogen, C1-6-alkoxy, (CRiiiRiv)n-phenyl; Ri and Rii denote H, C1-6-alkyl -C(O)-C1-6-alkyl; Riii and Riv denote C1-6-alkyl; m equals to 1 or 2, n equals 0 or 1; as well as to pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition, as well as to use of compounds of formula (I), (I-a) or (1-b).

EFFECT: obtaining novel biologically active compounds having activity on V1a receptor.

12 cl, 48 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new oxoazepanylacetamide and oxoazepanylphenoxyacetamide derivatives, or to their stereoisomers or pharmaceutically acceptable salts described by general formula I where Q means O, S or N(R25); R25 means H; R80 is C6arylC1-4alkyl substituted by one or two substituted independently chosen from R3 groups; each R3 is independently chosen from a group including C1-4alkyl, C1-4alkoxy group, C2-6alkenyloxy group, halogen, C6aryloxy group, N(R20)(R21), R50, heteroaryl chosen from pyridine and thiazol where each alkoxy group and heteroaryl has optionally up to three substitutes independently chosen from R61 groups; and alkyl has optionally three substitutes independently chosen from R60 groups; or two R3 groups when they are present on carbon neighbours, together can form a fragment of formula -(O)a-(CH2)b-(O)c-(CH2)d-(O)e- where a, c and e independently mean 0 or 1, and both b and d independently mean 0, 1, 2 or 3; provided the fragment does not contain two oxygen neighbors and summed a, b, c, d and e are equal to 3 at least; R1 is chosen from a group including H, C1-4alkyl, C6arylC1-4alkyl; each R60 independently is chosen from a group including C1-C6a alkoxy group, NR12R13, halogen, heterocycloalkyl, such as piperidine; each R61 independently is chosen from a group including R60 and C1-C6alkyl; X means a group of formula -(CH2)n- where n means 2 or 3; or a group of formula II where Y means CH2, S; R75 and R76 means H; Z means C6aryl or heteroaryl, such as pyridine; each of which has optionally one substitutes chosen from R2 groups; R2 is chosen from a group including H, C1-4alkyl, halogen, heterocycloalkylC1-4alkyl, C6arylC1-4alkylaminoC1-4alkyl and a group of formula -(CH2)fN(R11)-(R10); where each heterocycloalkyl, arylalkylaminoalkyl has oprtionally one substitute chosen from R61 groups; f means 1; R11 means H; R10 means C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, aryl, C6arylC1-4alkyl, heteroarylC1-4alkyl where aryl has optionally one substitute chosen from R61 groups; each R12 and R13 independently mean C1-4alkyl; each R20 and R21 independently mean C1-4alkyl where alkyl has optionally one substitute chosen from R60 groups; and provided that the compound does not represent N-(4-ethoxybenzyl)-N-(2-oxoazepane-2-yl)-2-phenoxyacetamide or N-[(2-fluorophenyl)methyl]-N-(2- oxoazepane-3-yl)-2,2-diphenylacetamide. Also, the invention refers to a pharmaceutical composition of the compound of formula I, to methods of treating HCV viral infection and methods of relieving the symptoms of HCV viral infection with using the compound of formula I.

EFFECT: there are produced new oxoazepanylacetamide and oxoazepanylphenoxyacetamide derivatives showing HCV replication inhibiting activity.

1 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology and neurology and can be applied in treatment of oncologic patients with accompanying Parkinson's disease. For this purpose before carrying out anti-tumour chemotherapy carried out is session of gravitation discrete plasmapheresis by apparatus MSC+"Haemonetics" in mode of plasma obtaining protocol, which is depleted of leucocytes, with speed of blood separation 4800 turns per minute, with volume of plasma extraction 800-1200 ml. As plasma-replacing solutions applied are Refortan 10%, Voluven 6%, Refortan 6% and crystalloid solutions: Disol, Chlosol, Reamberine. After that, carried out are two repeated sessions of plasmapheresis with interval 48-72 hours. During repeated hospitalisations of patients into the clinic with interval 2-3 months sessions of plasmapheresis are carried out in same mode.

EFFECT: method makes it possible to ensure possibility of carrying out chemotherapy for said category of patients in full volume.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medical equipment. Column contains case, upper and lower lids, connecting pipes, caps, hemosorbent and filters. In upper lid installed is air-duct, whose one end is connected with upper lid, external end being provided with connecting pipe. Lower lid, whose internal part is made cylindrical, contains passing through it branch pipe, on whose upper surface lock element is located. Lower part of branch pipe is provided with inlet connecting pipe. Hole is hermetically closed by elastic puncture-proof material Outlet connecting pipe is located on periphery of lower lid. All connecting pipes interact with detachable caps by means of sealing connection Luer-lock. Outlet filter is installed into internal cylindrical part of lower lid and is made from material, which has open-cell elastic polyhedral three-dimensional structure with porosity to 98%, size of whose pores is less than size of sorbent granules. Branch pipe passes through said filter. In case installed is interaction with it membrane, located between upper lid and butt end of upper part of branch pipe and having at least one hole, whose size is smaller than size of sorbent granules. Sorbent is located between membrane and outlet filter and is in column in moisturised state in air medium, which has humidity from 90% to 100%, or under layer of liquid.

EFFECT: invention makes it possible to reduce hydrodynamic resistance and increase safety.

18 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to efferent therapy, and can be used in treating autoimmune, metabolic and other diseases. That is ensured by cascade plasma filtration with using a device comprising a fractionator having one input and two outputs, supplied by a membrane filter dividing an internal volume of the fractionator on an internal and external space for a concentrate and a filtrate. The input and one of the outputs are designed to be coupled with the internal space of the fractionator, and the second output - with its external space. Before the input of the fractionator, there are mounted air trap and pressure sensor. Also, the device comprises a plasma container, a washing isotonic solution container T-jointed with a plasma or washing isotonic solution branch to the input of the fractionator, a washing liquid and/or concentrated plasma macromolecules tank connected via the branch with the output from the internal space of the fractionator. A pump segment mounted in the plasma or washing isotonic solution branch to the input of the fractionator, clamps fixed on the branches connected to the outputs of the fractionator, and also to the outputs of the plasma tank and washing isotonic solution tank. Plasma is supplied to the fractionator where it is divided on filtrate and concentrate. While dividing plasma, input pressure in the fractionator is measured, and if reaching the pressure value 100-150 mm hg, the division process is continued with taking the concentrate periodically or simultaneously to be removed from the internal space of the fractionator. The concentrate is taken at rate 5-20% of plasma perfusion rate until reaching the input pressure in the fractionator 150-250 mm hg. When reaching the maximum rate, the plasma division process is stopped that is followed with washing of the fractionator through the internal or external space, including in a continuous flow mode, then plasma division on the filtrate and concentrate is started again.

EFFECT: inventions allow providing high selectivity of target component removal, reducing loss of useful components of blood plasma.

9 cl, 3 tbl, 1 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly blood separation apparatuses. The apparatus comprises blood sampling and erythromass return branches 1, 2 equipped with catheters 6, a plasmafilter attached between the branches 1, 2, plasma drainage branch 3 and saline and anticoagulant feed branches 4, 5. The blood sampling branch 1 is equipped with a gate valve 8 and a blood pump 9, while the erythromass return branch 2 accommodates an air trap 12 and a gate valve 17. In the blood branch 1, the blood pump follows and precedes pressure sensors 10, 11. In the plasma drainage branch, the plasmafilter 7 is followed with an optical sensor 18 of plasmafilter blood leakage, a plasma pump 19 with a pressure sensor 20 and a plasma container 21. The saline feed branch from a salne container through an auxiliary pump and a saline detector is connected to the blood branch between the blood pump and plasmafilter or directly to the air trap 12. The anticoagulant feed branch connects the blood branch following the catheter through an anticoagulant pump and a citrate detector to an anticoagulant container. The air trap is equipped with a blood level detector 13 and an adjusting valve. The erythromass return branch following the air trap has a pocket air detector.

EFFECT: provided self-regulation and safety parametres checkout.

2 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly blood separation apparatuses. The apparatus comprises a blood sampling branch 1 and an erythromass return branch 2 with their free ends T-jointed with a catheter, a plasmafilter attached between said branches, a plasma drainage branch 3 and saline and anticoagulant feed branches 4,5. The blood sampling branch 1 is equipped with a gate valve 8 and a blood pump 9, while the erythromass return branch 2 accommodates an air trap 14 and a gate valve 19. In the blood branch, the pump is followed with a storage container 10 with a container weight recording element 11 and a blood pump 12 with a pressure sensor 13. The plasma drainage branch 3 following the plasmafilter 7 is supplied with an optical sensor 20 of plasmafilter blood leakage, a plasma pump 21 with a pressure sensor 22 and a plasma container 23; the saline feed branch 4 connects the blood branch between the gate valve and the blood pump through a supplementary pressure sensor, a gate valve and a saline detector with a saline container. The anticoagulant feed branch 5 connects the blood branch 1 blood to the gate valve 8 through an anticoagulant pump 28 and a citrate detector 29 with an anticoagulant container 30. The air trap 14 is equipped with a blood level detector and an adjusting valve, and the erythromass return branch following the air trap has a pocket air detector 18.

EFFECT: provided self-regulation and safety parametres checkout.

4 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to intensive therapy, and can be used in treating pathologies of pathogenesis associating microcirculation disturbance related processes. That is ensured by perfusion of an organ or a vascular region with activated blood cells generated by reaction thereof with a blood borne preparation through an arterial or venous bed. Perfusion blood volume is 0.2 to 2.0% of total blood volume, blood borne preparation volume is 10-70% of perfusion blood volume. Hemoperfusion rate is 5-10 ml/min. The therapeutic course includes 4 hemoperfusion procedures every 2-3 days.

EFFECT: method allows providing considerably enhanced blood supply in organs and tissues with simultaneous reduced perfusion blood volume due to development of optimum balance of arachidonic acid metabolites with prevailing vasodilating compounds.

3 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely, to efferent methods in surgery, and can be used in treating peritonitis patients. That is ensured by prolonged venovenous hemofiltration. In 2 hours after the procedure started, through a catheter inserted in a subclavian vein or a abdominal aorta with using a peristaltic pump for 15 minutes 250 ml of HyperHAES solution is introduced.

EFFECT: method allows higher effectiveness of detoxification ensured by an effect of endotoxin redistribution in a vascular bed from an interstitial space owing to introducing the hydroxyethyl starch solution followed by endotoxin elimination from the vascular bed by hemofiltration.

1 tbl, 1 ex

FIELD: process engineering.

SUBSTANCE: invention relates to membrane appliances intended for micro- and ultra-filtration. Membrane module (MM) for separation of media and/or mass exchange comprises set of porous membranes 1, relief elements (RE) 2 and sealing appliances (SA) that form alternating chambers of separated medium (SM) and permeate (P) 9. REs represent threads secured to surface M to form channels oriented along and across chambers SM and P open in direction of SM and P feed. Separation membrane device comprises casing (K) 14, SM manifold 8 with SM feed branch pipe 7 and P manifold 13 with P discharge branch pipe or SM manifolds feed branch pipes 17 and SM discharge branch pipes 18 and P manifold 13 with P discharge branch pipe 12 arranged in MM casing made up of the set of porous membranes with RE and SA that form alternating SM and P chambers, are made up of threads secured to surface M to form channels oriented along and across chambers SM and P open in direction of SM and P feed.

EFFECT: ease of manufacture, higher efficiency and possibility to use practically any material, including track (nuclear) materials as membrane material.

51 cl, 12 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to anesthesiology and resuscitation, and can be used in states accompanied by massive blood loss. For this purpose, 5 and 3 days prior to a surgery, autoblood is sampled in amount 10 % of circulating blood volume (CBV) in each sampling to be divided on plasma and erythrocyte concentrate. For 5 preoperative days, iron preparations are administered in a therapeutic dose. Also, the surgery is preceded with analysing patient's fluid deficiency. 40 minutes prior to the surgery, 12.5 % dicynone 500 mg, one volume of autoplasma are introduced, and infusion of a rated dose of 5 % glucose and 6 % hydroxyethyl starch (HES) 500 ml is started. If the intraoperative blood loss is suggested to be 15-30 % of the CBV, additionally 6 % HES 250 ml, prednisolone in dosage 2-4 mg/kg of body weight and one volume of erythrocyte concentrate are administered. If the estimated intraoperative blood loss exceeds 30 % of the CBV, the second volumes of autoplasma and erythrocyte concentrate, another introduction of dicynone in the same dosage, 6 % HES 250 ml, prednisolone in dosage 7 - 10 mg/kg of body weight are required. Within 30 and 60 minutes after the surgery, dicynone is injected in the same dosage. 5 hours after the surgery, filter drainage fluid is returned. 6 hours after the surgery, coagulation time is determined, and if observing no hypocoagulation, Clexane is introduced in a preventive dose.

EFFECT: method allows to provide early activation of erythropoiesis combined with improved erythrocyte morphology and blood haemostatic function, considerably reduced risk of complications connected with massive transfusion of donor blood products, as well as prevented edema of interstitial spaces and development of multiple-organ-failure syndrome due to maintained effective transcapillary exchange.

5 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatocosmetology and can be used for face and neck skin rejuvenation in women. For this purpose plasmapheresis in mode of discontinuous flow separation with sampling of 800-1000 ml of blood is carried out. In course of carrying out plasmapheresis after the first cycle, native plasma is taken and immediately introduced intradermally papularly on Langer lines. Diametre of papules is 0.5-1 cm, distance between them is 1.5-2.5 cm. Total volume of introduced plasma is 5-10 ml. Course consists of 2-3 procedures after 12-16 days.

EFFECT: method allows to increase efficiency of face and neck skin rejuvenation in women due to combination of local and systemic impact of plasma, which possesses high tropism to skin cells, which ensures formation of new collagen in skin.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: stock solution of albumin of the pH value 5 to 9 is brought into contact to a solid adsorbent affinity of which to at least a portion of used stabiliser molecules is higher than that of albumin to appropriate stabiliser molecules, and separated from the adsorbent. The aqueous solution of albumin is applied for preparing an agent for treating hypoalbuminemia, as a blood substitute, a respective plasma substitute, for extracorporeal blood clearance by apheresis or albumin dialysis, for better functioning of circulation system, kidneys and/or brain of the patient.

EFFECT: invention allows producing the to albumin solution with the decreased content of a stabiliser and higher coupling capacity.

24 cl, 4 ex, 2 tbl, 8 dwg

Up!